Business News • PR NewsWire • Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018

Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018

Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018

BURLINGTON, Mass., Sept. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increasing use of U.S. regulatory-approved agents -- Pfizer's Lyrica (pregabalin), Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeri

View More : http://www.prnewswire.com/news-releases/driven-by-sales-of-lyrica-cymbaltaxeristar-and-savella-the-fibromyalgia-drug-mar...

Releted News by prnewswire

International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA

Pittsburgh's Ultimate Haunted House Knows What Scares You